New York, NYNCT07163273Now EnrollingIRB Ready

Pancreatic Ductal Adenocarcinoma Clinical Trial in New York, NY

Access cutting-edge pancreatic ductal adenocarcinoma treatment through this clinical trial at a research site in New York. Study-provided care at no cost to qualified participants.

Sponsored by Northwell Health

Quick Self-Assessment

See if you qualify for this New York location

Preparing your pre-screening questions…

Expert Care in New York

Access pancreatic ductal adenocarcinoma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related pancreatic ductal adenocarcinoma treatment provided free

Apply for This New York Location

Check if you qualify for this pancreatic ductal adenocarcinoma clinical trial in New York, NY

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to New York

    Convenient for NY residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit New York site if eligible
  4. 4Begin participation

About This Pancreatic Ductal Adenocarcinoma Study in New York

A prospective, interventional, single-center, single-arm, open-label, phase II study for patients with metastatic pancreatic cancer. The intervention consists of monthly alternating standard chemotherapy regimens-NALIRIFOX and GnP. The hypothesis is that induction therapy with alternating NALIRIFOX and GnP has better efficacy compared to historical observation.

Sponsor: Northwell Health

Who Can Participate

Inclusion Criteria

\>18 years of age
Histologically proven pancreatic ductal adenocarcinoma, poorly differentiated carcinoma, or adenosquamous carcinoma
Radiographic evidence of metastatic disease
At least 1 measurable target lesion per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Metastatic relapse of previously resected pancreatic cancer is allowed provided the patient is more than 6 months from last SOC adjuvant treatment
ECOG PS 0-1
Laboratory assessments within 14 days as indicated below:
Hemoglobin \> 9.0 g/dL (patients with hemoglobin \< 9 g/dL may be transfused prior to study enrollment)
Platelet count \> 100 x 10\^9/L
Absolute neutrophil count (ANC) \> 1.5 x 10\^9/L
Total bilirubin \< 3 x upper limit of normal (ULN)
Aspartate transaminase (AST) and alanine transaminase (ALT) \< 3 x ULN (if liver metastases are present, AST and ALT \< 5 x ULN is permitted.
Creatinine ≤1.5 ULN
Creatinine clearance \> 40 mL/min as calculated by Cockcroft-Gault formula
APTT (aPTT) ≤ 1.5 × ULN. For subjects receiving unfractionated heparin \< 2.5 × ULN, or within acceptable range considered by the investigator.
PT/INR INR ≤ 1.5 × ULN. For subjects receiving warfarin, 2.0 -3.0, or within acceptable range considered by the investigator.
Women of childbearing potential must be surgically sterile or postmenopausal or must have a negative pregnancy test (serum or urine) prior to study enrolment and must use effective barrier contraception or abstinence during the treatment period. Oral, implantable, or injectable contraceptives may be affected by cytochrome P450 interactions and therefore are not considered effective for this study. Male patients must be surgically sterile or use effective contraception or abstinence during the treatment period. The definition of effective contraception will be based on investigator discretion. Female and male patients are advised to use effective contraceptives for at least 9 months after the last treatment dose.
Ability to understand and willing to sign informed consent form

Exclusion Criteria

A history of other disease, metabolic dysfunction, physical examination finding or clinical laboratory test result suspicious of a disease or condition which, in the opinion of the investigator, would compromise patient safety due to risk of treatment complications or could affect interpretation of the study results
Ampullary, acinar, squamous, and neuroendocrine histology
Presence of central nervous system metastases
Life expectancy \< 12 weeks
Pregnant or breastfeeding women
Prior neuropathy \> grade 1 as per CTCAE v5
Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better.
Major surgery within 4 weeks prior to initiation of the study treatment, without full recovery
Any past chemotherapy delivered for metastatic pancreatic cancer
Known somatic or germline mutations in BRCA1, BRCA2, or PALB2
Active second malignancy whose prognosis has a high likelihood of impacting survival
Any other medical or social condition deemed by the investigator to be likely to interfere with a subject's ability to sign informed consent, cooperate and participate in the study, or interfere with the interpretation of the results. Patients also unwilling or unable to comply with study procedures and/or study visits, including long-term follow-up for survival.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in New York?

Yes, this clinical trial (NCT07163273) has an active research site in New York, NY that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Pancreatic Ductal Adenocarcinoma Treatment Options in New York, NY

If you're searching for pancreatic ductal adenocarcinoma treatment options in New York, NY, this clinical trial (NCT07163273) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our New York research site is actively enrolling participants for this clinical trial. You'll receive care from experienced pancreatic ductal adenocarcinoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all pancreatic ductal adenocarcinoma clinical trials near you to find additional studies recruiting in your area.

More Alzheimers Disease Trials in New York, NY

See all alzheimers disease clinical trials recruiting in New York — not just this study.

Browse Alzheimers Disease Trials in New York →

Browse More Trials by Condition

Alzheimers Disease TrialsUlcerative Colitis TrialsAtopic Dermatitis TrialsInterstitial Cystitis TrialsAll Conditions →

Ready to Join in New York?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · New York, NY